According to the report, the global immunotherapy drugs market was valued at approximately USD 138.4 billion in 2018 and is expected to generate around USD 330.4 billion by 2025, at a CAGR of around 13.24% between 2019 and 2025.
New York, NY, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Zion Market Research has published a new report titled “Immunotherapy Drugs Market by Drug Type (Adult Vaccines, Monoclonal Antibodies, Checkpoint Inhibitors, Interleukins, Interferon Alpha & Beta, and Others), by Therapeutic Application (Autoimmune & Inflammatory Diseases, Cancer, Infectious Diseases, and Others), and by End-User (Hospitals, Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018—2025”. According to the report, the global immunotherapy drugs market was valued at approximately USD 138.4 billion in 2018 and is expected to generate around USD 330.4 billion by 2025, at a CAGR of around 13.24% between 2019 and 2025.
Immunotherapy, also referred to as biological therapy, uses the body’s natural defense system to fight cancer cells and other infections. Drugs used in immunotherapy either suppress or enhance the body’s immune system. Immunotherapy drugs generate an immune response and activate the production of antibodies. Immunotherapy offers lesser side effects over traditional therapies, such as chemotherapy, surgery, radiation therapy etc., as it uses the body’s natural defense mechanism. Immunotherapy seems to be a promising treatment option for complex disorders, such as cancer and autoimmune diseases.
Browse through 88 Tables & 30 Figures spread over 110 Pages and in-depth TOC on “Global Immunotherapy Drugs Market: By Type, Size, Share, Applications, Analysis and Forecast, 2018—2025”.
Request Free Sample Report of Global Immunotherapy Drugs Market Report @ https://www.zionmarketresearch.com/sample/immunotherapy-drugs-market
The prevalence of cancer is growing worldwide and it was the second leading cause of death in the year 2018. As per the World Health Organization (WHO) 2018 estimates, there were about 18.1 million new cancer cases and 9.6 million global deaths caused by cancer. The incidence of lifestyle-related disorders is rapidly increasing, which, in turn, is likely to drive the demand for immunotherapy drugs market in the future. The increasing preference for targeted therapy with lesser side-effects over traditional therapy is anticipated to further fuel the immunotherapy drugs market in the future. Additionally, the emergence of new biosimilars, rapid drug approvals, and increased demand for monoclonal antibodies (mAbs) are projected to boost the immunotherapy drugs market growth over the estimated timeframe. Other factors likely to contribute toward the immunotherapy drugs market growth are rising geriatric population base, increasing health awareness, increased disposable income and healthcare spending, and favorable reimbursement policies.
The global immunotherapy drugs market is segmented based on drug type, therapeutic application, and end-user. By drug type, the market is segmented into adult vaccines, monoclonal antibodies, checkpoint inhibitors, interleukins, interferon alpha and beta, and others. Preventive vaccines and therapeutic vaccines comprise the adult vaccines segment. Monoclonal antibodies drug type segment held the largest share of the global immunotherapy drug market in 2017, owing to the preference for targeted therapy with lesser side effects. By therapeutic application, this global market is segmented into autoimmune and inflammatory diseases, cancer, infectious diseases, and others. Cancer segment is further divided into the solid tumor and malignant. The cancer therapeutic application segment held the largest share of global immunotherapy drugs market, owing to increasing cancer prevalence globally. Hospitals, clinics, and others form the end-user segment of the global immunotherapy drugs market. Hospitals dominated the immunotherapy drugs market in 2017 and are expected to lead in the future as well.
Download Free Report PDF Brochure: https://www.zionmarketresearch.com/requestbrochure/immunotherapy-drugs-market
The North American region is a developed immunotherapy drugs market with a revenue share of about 40% of the global market. The presence of key players, well-developed healthcare systems in Canada and the U.S., and the growing prevalence of lifestyle-related disorders, such as cancer, infections etc. are predicted to drive the region’s immunotherapy drugs market in the future. Additionally, the growing health awareness and favorable reimbursement policies are projected to boost the market growth. The demand for personalized or targeted therapy is increasing rapidly, owing to lesser side effects over traditional therapy, which, in turn, is likely to boost the demand for monoclonal antibodies. North America is estimated to register the highest CAGR over the forecast time period to retain its leading position in the market. The U.S. is the most dominating country in the North American immunotherapy drugs market, owing to the presence of major biopharmaceutical companies, massive government funding/grants for research and drug development activities, strategic R&D collaborations with academic institutes, favorable reimbursement policies, and increasing medicine awareness among the patients. Furthermore, the availability of developed healthcare infrastructure is anticipated to further propel the immunotherapy drugs market in the years ahead.
The second largest region for immunotherapy drugs market is Europe. This can be attributed to the rise in lifestyle-related disorders, growing demand for monoclonal antibodies, adoption of targeted therapy, and robust healthcare infrastructure facility. At the country level, Germany, UK, and France are major contributors to the immunotherapy drugs market. Germany held the largest share in the European immunotherapy drugs market followed by the UK. UK is expected to register the highest CAGR over the forecast time period, owing to an increasing preference for targeted therapy, government grant for research and development (R&D)activities, and rising investments for R&D by biopharmaceutical companies.
Browse the full “Immunotherapy Drugs Market by Drug Type (Adult Vaccines, Monoclonal Antibodies, Checkpoint Inhibitors, Interleukins, Interferon Alpha & Beta, and Others), by Therapeutic Application (Autoimmune & Inflammatory Diseases, Cancer, Infectious Diseases, and Others), and by End-User (Hospitals, Clinics, and Others): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018—2025” Report at https://www.zionmarketresearch.com/report/immunotherapy-drugs-market
The Asia Pacific region is likely to exhibit the highest CAGR over the forecast time period. This can be attributed to increased disposable income, growing lifestyle-related disorders, rising healthcare expenditure, and increasing awareness about health disorders. Additionally, the rising aging population and increasing cancer cases are anticipated to further fuel the immunotherapy drugs market in the region. China, India, and Japan represent dominant countries of this market, whereas China is expected to witness the highest CAGR followed by India over the estimated time period.
The Middle Eastern and African market is projected to grow slowly over the estimated timeline. The Latin American immunotherapy drugs market witnessed moderate growth in the past. The region is projected to exhibit considerable growth in the immunotherapy drugs market in the future.
Inquire more about this report before purchase @ https://www.zionmarketresearch.com/inquiry/immunotherapy-drugs-market
Some key players of the immunotherapy drugs market include F. Hoffmann-La Roche AG, Amgen, Inc., Novartis International AG, AbbVie, Inc., Merck & Co., Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca plc, and Johnson & Johnson, among others.
Request customized copy of report @ https://www.zionmarketresearch.com/custom/1811
This report segments the global immunotherapy drugs market into:
Global Immunotherapy Drugs Market: By Drug Type
- Monoclonal Antibodies
- Adult Vaccines
- Preventive Vaccines
- Therapeutic Vaccines
- Checkpoint Inhibitors
- Interferons Alpha and Beta
Global Immunotherapy Drugs Market: By Therapeutic Application
- Solid Tumor
- Autoimmune and Inflammatory Diseases
- Infectious Diseases
Global Immunotherapy drugs Market: By End-User
Global Immunotherapy Drugs Market: By Region
- North America
- The U.S.
- Asia Pacific
- Latin America
- The Middle East and Africa
- Osteoarthritis Drug Market: https://www.zionmarketresearch.com/report/osteoarthritis-drug-market
- Erectile Dysfunction Drugs Market: https://www.zionmarketresearch.com/report/erectile-dysfunction-drugs-market
- Thrombosis Drug Market: https://www.zionmarketresearch.com/report/thrombosis-drug-market
- Ophthalmic Drugs Market: https://www.zionmarketresearch.com/report/ophthalmic-drugs-market
- Prostate Cancer Therapeutics Market: https://www.zionmarketresearch.com/report/prostate-cancer-therapeutics-market
Zion Market Research is an obligated company. We create futuristic, cutting edge, informative reports ranging from industry reports, company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.
Follow Us LinkedIn: https://www.linkedin.com/company/zion-market-research
Follow Us Twitter: https://twitter.com/zion_research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651